Mostrar el registro sencillo del ítem
Systemic Inflammation in Oncologic Patients Undergoing Systemic Treatment and Receiving Whey Protein-Based Nutritional Support
dc.contributor.author | Herrera-Martínez, Aura D. | |
dc.contributor.author | Navas Romo, Ana María | |
dc.contributor.author | León-Idougourram, Soraya | |
dc.contributor.author | Muñoz Jiménez, Concepción | |
dc.contributor.author | Rodríguez-Alonso, Rosa | |
dc.contributor.author | Manzano García, Gregorio | |
dc.contributor.author | Camacho-Cardenosa, Marta | |
dc.contributor.author | Casado-Díaz, Antonio | |
dc.contributor.author | Gálvez-Moreno, M. Ángeles | |
dc.contributor.author | Molina Puertas, María José | |
dc.contributor.author | Jurado Roger, Aurora | |
dc.date.accessioned | 2024-05-27T12:56:08Z | |
dc.date.available | 2024-05-27T12:56:08Z | |
dc.date.issued | 2024 | |
dc.identifier.uri | http://hdl.handle.net/10396/28390 | |
dc.description.abstract | There is increasing evidence about the role of inflammation in sarcopenia and tumor progression; thus, its modulation would represent a valuable strategy for improving clinical outcomes in patients with cancer. Several studies have reported that whey protein has significant anti-inflammatory and antioxidant characteristics in humans. We aimed to evaluate the effects of whey protein-based oral nutritional support on circulating cytokines in patients with solid tumors undergoing systemic treatment. Forty-six patients with solid tumors of different origin and undergoing systemic treatment were evaluated. Nutritional support with two daily whey protein-based oral supplements was administered. Circulating levels of IL-6, IL-8, IL-10, MCP-1 and IP-10 were determined. Nutritional evaluation included anthropometric, instrumental and biochemical parameters. Over 63% of the evaluated patients underwent surgery, 56.5% required chemotherapy and almost 50% received combined treatment. Patients with resected primary tumor presented with lower baseline IL-6 (p < 0.05) and IP-10 (p < 0.001); after three months of nutritional support, they presented with lower IL-8 (p < 0.05) and tended to present lower IL-6 and IP-10 (p = 0.053 and 0.067, respectively). Significant positive correlations between circulating cytokines, C-reactive protein and ferritin were observed; similarly, negative correlations with anthropometric and biochemical nutritional parameters were noticed (p < 0.05). We did not observe significant changes in circulating cytokine levels (IL-6, IL-8, IL-10, MCP-1 and IP-10) in patients with cancer undergoing systemic treatment after three months of nutritional support with whey protein-based oral supplements. According to a univariate analysis in our cohort, circulating IL-8 was associated with mortality in these patients, additionally, MCP-1 and IP-10 tended to correlate; but an age- and sex-adjusted multivariate analysis revealed that only baseline MCP-1 was significantly associated with mortality (OR 1.03 (95% CI: 1.00–1.05)). In conclusion, surgery of the primary solid tumor and combination treatment allow significant reduction in circulating cytokine levels, which remained stable while patients received nutritional support with whey protein-based oral supplements over three months. The role of MCP-1 as an independent factor for mortality in these patients should be further evaluated. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.source | Herrera-Martínez, A.D.; Navas Romo, A.; León-Idougourram, S.; Muñoz-Jiménez, C.; Rodríguez-Alonso, R.; Manzano García, G.; Camacho-Cardenosa, M.; Casado-Diaz, A.; Gálvez-Moreno, M.Á.; Molina Puertas, M.J.; et al. Systemic Inflammation in Oncologic Patients Undergoing Systemic Treatment and Receiving Whey Protein-Based Nutritional Support. Int. J. Mol. Sci. 2024, 25, 5821. | es_ES |
dc.subject | Inflammation | es_ES |
dc.subject | Cytokines | es_ES |
dc.subject | Whey protein | es_ES |
dc.subject | Cancer | es_ES |
dc.title | Systemic Inflammation in Oncologic Patients Undergoing Systemic Treatment and Receiving Whey Protein-Based Nutritional Support | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/ijms25115821 | |
dc.relation.projectID | Gobierno de España.ISCIII/PI23/01554 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |